newsfilter
← Latest News
Business Wire·

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

EQ

Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative colitis study recently